Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Century Therapeutics, Inc.NASDAQ: IPSC
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $0, compared with $109.16M a year earlier. Trailing-twelve-month revenue was $0. Over 3 fiscal years it compounded at +175.9% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $4.72M (-95.7%) for the fiscal year ending Dec 2026, a slowdown from the +1556.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $0— QoQ
- Last fiscal yearDec 2025
- $109.16M+1556.8% YoY
- LTMMar 2026
- $0-100.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -100.0% | — | — |
| 1 year | +1556.8% | -95.7% | -1652.4 pp |
| 3-year CAGR | +175.9% | -77.9% | -253.8 pp |
| 5-year CAGR | -17.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 109.16M USD
- Year-over-year change
- +1556.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.16M | +1556.8% |
| FY2024 | 2024-12-31 | 6.59M | +194.8% |
| FY2023 | 2023-12-31 | 2.24M | -57.0% |
| FY2022 | 2022-12-31 | 5.2M | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's LTM Mar 2026 revenue of $0 is the 5th highest of the 8 companies compared; the peer median is $333.14K.
- Its year-over-year change of -100.0% is the 5th highest of 6, against a peer median of +95.8%.
- Over three fiscal years its annual growth of +175.9% compares with a peer median of +89.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $151.12M | +6.3% | -2.4% | |
| LTM Mar 2026 | $32.73M | +309.6% | +180.5% | |
| LTM Mar 2026 | $1.41M | +2148.9% | — | |
| LTM Mar 2026 | $333.14K | +95.8% | — | |
| LTM Mar 2026 | $0 | -100.0% | +175.9% | |
| LTM Mar 2026 | $0 | -100.0% | — | |
| LTM Mar 2026 | $0 | — | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding IPSC) | $333.14K | +95.8% | +89.0% | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 5.2M | 2.24M | 6.59M | 109.16M |
| Cost of Revenue | 4.58M | 0 | 0 | 0 | 13.1M |
| Gross Profit | (4.58M) | 5.2M | 2.24M | 6.59M | 96.06M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 88.0% |
| Research & Development | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M |
| Selling, General & Admin | 14.65M | 31.86M | 34.71M | 33.16M | 24M |
| Operating Expenses | 90.3M | 139.03M | 148.78M | 144.73M | 111.1M |
| Depreciation & Amortization | 4.58M | 8.44M | 13.04M | 13.3M | 13.1M |
| EBITDA | (89.92M) | (121.2M) | (121.21M) | (111.47M) | 3.45M |
| EBITDA Margin | — | -2331.2% | -5423.2% | -1691.8% | 3.2% |
| Operating Income | (94.88M) | (133.83M) | (146.55M) | (138.14M) | (15.04M) |
| Operating Margin | — | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Interest Income | 898K | 2.99M | 12.68M | 13.01M | 7.35M |
| Interest Expense | 1.28M | 0 | 540K | 0 | 0 |
| Other Income / Expenses | (898K) | 2.99M | 11.75M | 13.36M | 5.39M |
| Income Before Tax | (95.78M) | (130.84M) | (134.79M) | (124.78M) | (9.65M) |
| Pre-Tax Margin | — | -2516.7% | -6031.0% | -1893.7% | -8.8% |
| Income Tax Expense | 43K | 91K | 1.88M | 1.79M | (68K) |
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Net Margin | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (Basic) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| EPS (Diluted) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| Weighted Avg Shares | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
| Weighted Avg Shares (Diluted) | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.